Sponsor study identifier
interventional
50
1 country
1
Study Start
January 28, 2024
Actual (reported)Primary Completion
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The main goal of this clinical trial is to evaluate the feasibility of conducting a large-scale clinical trial testing a program containing several aspects for reducing the effects of air pollution on cardiovascular health (which is named the hybrid program hereafter) in adult patients (18 years or older) with atherosclerotic cardiovascular disease. Furthermore, we seek to answer how much patients adhere to and are satisfied with implementing the hybrid program, and what problems executing this program will bring for patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 28, 2024
Actual (reported)February 7, 2024
Actual (reported)February 15, 2024
Actual (reported)March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Feasibility of conducting the trial
Recruitment rate defined as the proportion of participants randomized divided by the proportion of eligible participants
within 30 days
Adherence to the individual components of the hybrid strategy
within 30 days
Patient satisfaction with the hybrid strategy
within 30 days
A hybrid strategy inclusive of: 1. A one-page flashcard describing the adverse cardiovascular effects of air pollution and individual-level strategies to mitigate these effects 2. Alerting patients on polluted days (defined as air quality index (AQI) ≥ 131 \[33\]) by sending cell phone text messages and recommending to not go outdoors or minimize outdoor activities (especially exercising) on those days. This will also be accompanied by periodic phone calls to ascertain that the patients receive the messages and are attentive to them. 3. Wearing KN-95 facemasks (provided by the investigators of this study) as a physical barrier against air pollution on highly polluted days (defined as AQI ≥ 131) in case the patient cannot avoid going outdoors 4. Dietary intervention by encouraging patients to consume citrus fruits during days with AQI ≥ 131.
No active strategy (usual care) without any clear recommendations related to air pollution. A control card will be shared with the patients randomized to the control group
A hybrid strategy inclusive of: 1. A one-page flashcard describing the adverse cardiovascular effects of air pollution and individual-level strategies to mitigate these effects 2. Alerting patients on polluted days (defined as air quality index (AQI) ≥ 131 \[33\]) by sending cell phone text messages and recommending to not go outdoors or minimize outdoor activities (especially exercising) on those days. This will also be accompanied by periodic phone calls to ascertain that the patients receive the messages and are attentive to them. 3. Wearing KN-95 facemasks (provided by the investigators of this study) as a physical barrier against air pollution on highly polluted days (defined as AQI ≥ 131) in case the patient cannot avoid going outdoors 4. Dietary intervention by encouraging patients to consume citrus fruits during days with AQI ≥ 131
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Rajaie Cardiovascular Medical and Research Center
Tehran, 1995614331, Iran
Parham Sadeghipour, M.D
Rajaie Cardiovascular Medical and Research Center
First Submitted
February 7, 2024
First Posted
February 15, 2024
Study Start
January 28, 2024
Actual (reported)Any potential adverse events in intervention and control groups during the 30-day follow-up
within 30 days
Change in the health-related quality of life
within 30 days
Change in the level of anxiety
within 30 days
Contact the study team to confirm eligibility.
Primary Completion
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
March 5, 2024
Record last verified: 2024-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: